Rigel Pharmaceuticals shares surge 16.67% intraday after strong Q2 earnings and revenue guidance.

Rigel Pharmaceuticals, Inc. surged 16.67% intraday, driven by strong second-quarter earnings that exceeded analyst expectations, with revenue of $101.7 million and earnings per share of $3.28. The company's core products, Tavalisse and Gavreto, saw robust sales, contributing to a 76% year-over-year increase in product net sales to $58.9 million. Additionally, Rigel Pharmaceuticals, Inc. raised its full-year revenue guidance to $270 million to $280 million and expects to turn a net profit for the first time in 2025.